SGLT-2 Therapy Center

Young adults diagnosed with type 2 diabetes early in life often face a more aggressive disease course than older adults. While metformin has long served as the standard first-line therapy, many clinicians are now reconsidering whether a “metformin-first and wait” strategy is enough for this higher-risk population. As research continues …

Discover how SGLT-2 inhibitors are transforming diabetes care and enhancing cardiovascular health, offering a multifaceted approach to treatment.

SGLT-2 inhibitors are a class of drugs that are used to treat type 2 diabetes. They work by blocking the reabsorption of glucose in the kidneys, allowing glucose to be excreted in the urine. As a result, they can help to reduce blood glucose levels and improve glycemic control. In …

Patients with cardiac implantable electronic devices (CIEDs) who received an SGLT2i had a significantly lower incidence of atrial arrhythmia (AA) compared to placebo. 

DAPA-CKD trial results indicate a significant benefit for SGLT2 inhibitor dapagliflozin in reducing chronic kidney disease progression and mortality caused by kidney failure and cardiovascular disease, regardless of diabetes status. 

Dapagliflozin (Farxiga®) has been granted U.S. Food and Drug Administration (FDA)  Breakthrough Therapy Designation (BTD) for patients with chronic kidney disease (CKD), whether or not they have type 2 diabetes. 

In addition to clinical trials, does data from a meta-analysis of retrospective cohort studies support the benefits of SGLT-2 inhibitors?

Black patients may have lower odds of achieving target HbA1C levels on metformin and SGLT2 alone. 

Sodium-glucose cotransporter 2 (SGLT2) inhibitors were created to treat diabetes, but noted to ameliorate cardiovascular events. 

The case for why an SGLT2 inhibitor or GLP-1 receptor agonist should be initiated early in diabetes treatment, regardless of whether the patient is on insulin therapy.